Intra-Cellular Therapies Gross Profit 2013-2022 | ITCI

Intra-Cellular Therapies annual/quarterly gross profit history and growth rate from 2013 to 2022. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
  • Intra-Cellular Therapies gross profit for the quarter ending March 31, 2022 was $0.032B, a 120.77% increase year-over-year.
  • Intra-Cellular Therapies gross profit for the twelve months ending March 31, 2022 was $0.093B, a 171.47% increase year-over-year.
  • Intra-Cellular Therapies annual gross profit for 2021 was $0.076B, a 262.21% increase from 2020.
  • Intra-Cellular Therapies annual gross profit for 2020 was $0.021B, a 34191.8% increase from 2019.
  • Intra-Cellular Therapies annual gross profit for 2019 was $0B, a INF% increase from 2018.
Intra-Cellular Therapies Annual Gross Profit
(Millions of US $)
2021 $76
2020 $21
2019 $0
2018 $
2017 $0
2016 $0
2015 $0
2014 $1
2013 $3
2012 $3
Intra-Cellular Therapies Quarterly Gross Profit
(Millions of US $)
2022-03-31 $32
2021-12-31 $23
2021-09-30 $20
2021-06-30 $18
2021-03-31 $14
2020-12-31 $11
2020-09-30 $7
2020-06-30 $2
2020-03-31 $1
2019-12-31
2019-09-30
2019-06-30
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2018-03-31
2017-12-31 $0
2017-09-30 $0
2017-06-30 $0
2017-03-31 $0
2016-12-31 $0
2016-09-30 $0
2016-06-30 $0
2016-03-31
2015-12-31 $0
2015-09-30
2015-06-30 $0
2015-03-31 $0
2014-12-31 $0
2014-09-30 $0
2014-06-30 $0
2014-03-31 $0
2013-12-31 $1
2013-09-30 $1
2013-06-30 $1
2013-03-31 $1
2012-12-31
2012-09-30 $0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $5.459B $0.084B
Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular Therapies Inc. is headquartered in New York.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.213B 9.87
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.280B 16.23
Biohaven Pharmaceutical Holding (BHVN) United States $10.017B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.593B 0.00
Emergent Biosolutions (EBS) United States $1.775B 7.60
Arcus Biosciences (RCUS) United States $1.357B 34.40
Myovant Sciences (MYOV) United Kingdom $1.000B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.360B 0.00
Zymeworks (ZYME) Canada $0.346B 0.00
Ambrx Biopharma (AMAM) United States $0.149B 0.00
Enzo Biochem (ENZ) United States $0.116B 23.80
SQZ Biotechnologies (SQZ) United States $0.099B 0.00